September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Patients with ERBB2 exon 20 insertion mutations showed particularly encouraging outcomes – Elie G. Dib
Jun 15, 2023, 15:56

Patients with ERBB2 exon 20 insertion mutations showed particularly encouraging outcomes – Elie G. Dib

Excited to share that our study, published in JCO Precision Oncology, sheds light on the antitumor activity of pertuzumab plus trastuzumab (P + T) in advanced lung cancer patients with ERBB2 mutation or amplification. The Targeted Agent and Profiling Utilization Registry (TAPUR) Study demonstrated promising results, with a disease control rate of 37% and an objective response rate of 11%. Notably, patients with ERBB2 exon 20 insertion mutations showed particularly encouraging outcomes. These findings offer hope for heavily pretreated non-small-cell lung cancer patients. Grateful to the team and the American Society of Clinical Oncology for their support.

Source: